EUVIMEDEUVIMED entdecken
Crossref

Development of an Improved Adenovirus Vector and Its Application to the Treatment of Lifestyle-Related Diseases

Kahori Shimizu

Biological and Pharmaceutical Bulletin · 2024

DOI: 10.1248/bpb.b23-00837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Kahori Shimizu. Beteiligte Einrichtung: Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University. Hauptthemen laut MEDLINE: Adenoviridae, Diabetes Mellitus, Type 2, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeDiabetes Mellitus, Type 2Genetic TherapyGenetic VectorsLife StyleAnimalsHumansInsulin ResistanceLiverNon-alcoholic Fatty Liver Disease

Stichwörter der Autor:innen

adenovirus vectordiabetesgene therapylifestyle-related diseaselipidmetabolic dysfunction-associated steatotic liver disease

Autor:innen und Institutionen

  • Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University.
  • Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University.

Zitieren

APA

Shimizu, K. (2024). Development of an Improved Adenovirus Vector and Its Application to the Treatment of Lifestyle-Related Diseases. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00837

Vancouver

Shimizu K. Development of an Improved Adenovirus Vector and Its Application to the Treatment of Lifestyle-Related Diseases. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b23-00837

BibTeX
@article{Shimizu2024,
  author = {Shimizu, Kahori},
  title = {Development of an Improved Adenovirus Vector and Its Application to the Treatment of Lifestyle-Related Diseases},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2024},
  doi = {10.1248/bpb.b23-00837}
}
Kostenlos starten →